These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25058447)

  • 1. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
    Abdelbary GA; Aburahma MH
    J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation and evaluation of proniosomes containing lornoxicam.
    Madan JR; Ghuge NP; Dua K
    Drug Deliv Transl Res; 2016 Oct; 6(5):511-8. PubMed ID: 27255375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
    Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
    Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation Optimization and In-vitro and In-vivo Evaluation of Lornoxicam Ethosomal Gels with Penetration Enhancers.
    Li K; Gao S; Tian B; Shi Y; Lv Q; Han J
    Curr Drug Deliv; 2018; 15(3):424-435. PubMed ID: 29219057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proniosomes as a carrier system for transdermal delivery of tenoxicam.
    Ammar HO; Ghorab M; El-Nahhas SA; Higazy IM
    Int J Pharm; 2011 Feb; 405(1-2):142-52. PubMed ID: 21129461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of Niosomal Gel for Enhanced Transdermal Lornoxicam Delivery: In-Vitro and In-Vivo Evaluation.
    El-Ridy MS; Yehia SA; Mohsen AM; El-Awdan SA; Darwish AB
    Curr Drug Deliv; 2018; 15(1):122-133. PubMed ID: 28240177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niosomal gel of lornoxicam for topical delivery: in vitro assessment and pharmacodynamic activity.
    Kumbhar D; Wavikar P; Vavia P
    AAPS PharmSciTech; 2013 Sep; 14(3):1072-82. PubMed ID: 23818079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid.
    Wen MM; Farid RM; Kassem AA
    J Liposome Res; 2014 Dec; 24(4):280-9. PubMed ID: 24779560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery.
    Alsarra IA
    J Microencapsul; 2009 May; 26(3):272-8. PubMed ID: 18720197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro & in vivo studies on lornoxicam loaded nanoemulsion gels for topical application.
    Dasgupta S; Ghosh SK; Ray S; Kaurav SS; Mazumder B
    Curr Drug Deliv; 2014; 11(1):132-8. PubMed ID: 24266509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design.
    Aboelwafa AA; El-Setouhy DA; Elmeshad AN
    AAPS PharmSciTech; 2010 Dec; 11(4):1591-602. PubMed ID: 21063815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.
    Balfour JA; Fitton A; Barradell LB
    Drugs; 1996 Apr; 51(4):639-57. PubMed ID: 8706598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal Lipid Nanocarriers: A Potential Delivery System for Lornoxicam.
    Dasgupta S; Ray S; Dey S; Pal P; Mazumder B
    Pharm Nanotechnol; 2017; 5(1):32-43. PubMed ID: 28948909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
    Al-Mahallawi AM; Abdelbary AA; Aburahma MH
    Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-articular drug delivery from an optimized topical patch containing teriflunomide and lornoxicam for rheumatoid arthritis treatment: does the topical patch really enhance a local treatment?
    Xi H; Cun D; Xiang R; Guan Y; Zhang Y; Li Y; Fang L
    J Control Release; 2013 Jul; 169(1-2):73-81. PubMed ID: 23567043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transbuccal permeation, anti-inflammatory activity and clinical efficacy of piroxicam formulated in different gels.
    Attia MA; El-Gibaly I; Shaltout SE; Fetih GN
    Int J Pharm; 2004 May; 276(1-2):11-28. PubMed ID: 15113610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of methotrexate loaded niosomes by Box-Behnken design: an understanding of solvent effect and formulation variability.
    Zidan AS; Mokhtar Ibrahim M; Megrab NAE
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1450-1459. PubMed ID: 28420295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental optimization of Lornoxicam liposomes for sustained topical delivery.
    Joseph J; B N VH; D RD
    Eur J Pharm Sci; 2018 Jan; 112():38-51. PubMed ID: 29111151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of cellulose derivative and ethylene glycol on optimization of lornoxicam transdermal formulation.
    Shahzad Y; Khan Q; Hussain T; Shah SN
    Int J Biol Macromol; 2013 Oct; 61():26-32. PubMed ID: 23827761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.
    Rajabalaya R; David SR; Chellian J; Xin Yun G; Chakravarthi S
    Drug Deliv; 2016 Jun; 23(5):1578-87. PubMed ID: 26634274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.